跳至主要内容
临床试验/IRCT2015051010203N6
IRCT2015051010203N6已完成2 期

Evaluation of Spironolactone nano emulgel (1%) effect on skin characteristics and treatment of mild to moderate acne vulgaris in comparison with spironolactone gel 5%

Vice chancellor of research0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
11 years 至 45 years(—)
性别
All

入选标准

  • patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale, who were not satisfied with their previous acne therapies participated in the study after giving written informed consent
  • Exclusioncriteria: Patients were excluded if they had an uncontrolled systemic disease; had received topical antiacne therapy two months before or during the study or any systemic therapy with antibiotics, OCP, and spironolactone 30 days before or during the study; were known to be allergic or sensitive to any of the study medications or their components; had previously been treated with systemic retinoids; had a skin disease that might interfere with the diagnosis or evaluation of their hyperpigmentation; or were pregnant, or planning to become pregnant, and lactating.

排除标准

  • 未提供

研究者

发起方
Vice chancellor of research

相似试验